Royalty Pharma plc (NASDAQ:RPRX) Receives $41.67 Consensus PT from Analysts

Shares of Royalty Pharma plc (NASDAQ:RPRX - Get Free Report) have received an average rating of "Buy" from the seven ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $41.67.

RPRX has been the topic of a number of analyst reports. TD Cowen raised shares of Royalty Pharma to a "strong-buy" rating in a report on Tuesday, December 24th. StockNews.com raised shares of Royalty Pharma from a "hold" rating to a "buy" rating in a research note on Tuesday, November 5th. Finally, Citigroup cut their price target on shares of Royalty Pharma from $60.00 to $40.00 and set a "buy" rating for the company in a research note on Friday, October 25th.

Royalty Pharma Price Performance

Royalty Pharma stock traded up $3.29 during midday trading on Friday, reaching $29.49. 8,066,224 shares of the stock were exchanged, compared to its average volume of 3,142,627. The company's fifty day moving average is $25.94 and its 200-day moving average is $27.05. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.54. The firm has a market cap of $17.38 billion, a PE ratio of 15.28, a PEG ratio of 4.36 and a beta of 0.47. Royalty Pharma has a 52 week low of $24.05 and a 52 week high of $31.66.

Royalty Pharma Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 21st will be issued a dividend of $0.22 per share. This is a positive change from Royalty Pharma's previous quarterly dividend of $0.21. This represents a $0.88 dividend on an annualized basis and a yield of 2.98%. The ex-dividend date is Friday, February 21st. Royalty Pharma's dividend payout ratio is currently 43.52%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC purchased a new stake in Royalty Pharma during the 2nd quarter valued at about $250,000. Daiwa Securities Group Inc. raised its stake in Royalty Pharma by 4.5% during the 2nd quarter. Daiwa Securities Group Inc. now owns 27,694 shares of the biopharmaceutical company's stock worth $730,000 after acquiring an additional 1,180 shares during the period. American Century Companies Inc. raised its stake in Royalty Pharma by 13.0% during the 2nd quarter. American Century Companies Inc. now owns 60,468 shares of the biopharmaceutical company's stock worth $1,595,000 after acquiring an additional 6,955 shares during the period. Forsta AP Fonden raised its stake in Royalty Pharma by 138.8% during the 2nd quarter. Forsta AP Fonden now owns 235,900 shares of the biopharmaceutical company's stock worth $6,221,000 after acquiring an additional 137,100 shares during the period. Finally, Meeder Advisory Services Inc. raised its position in shares of Royalty Pharma by 12.7% during the second quarter. Meeder Advisory Services Inc. now owns 8,223 shares of the biopharmaceutical company's stock valued at $217,000 after buying an additional 926 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.